DOJ's $309M settlement with Apex Medical, announced in January 2026 and resolving allegations tied to more than $1 billion in claims for medically unnecessary amniotic wound grafts, is the clearest public map of how the government now builds a skin substitute False Claims Act case. The matter did not rest on a single theory. It combined a kickback-driven pricing spread claim, a medical necessity claim, and a marketer conduct claim, and DOJ has repeated the same three-part structure across the wound care cases that followed. A wound care provider evaluating its own exposure needs to test its billing against all three, not just the one that seems most obviously present.
Pricing Spreads and the Kickback Theory
The Apex Medical allegations centered on kickbacks the defendants received from a wholesale wound allograft distributor in exchange for directing orders toward specific products, kickbacks the defendants then shared with sales representatives to keep referrals flowing. Under the Anti-Kickback Statute, any remuneration tied to referrals or product volume is illegal regardless of the clinical outcome, and a claim submitted under a kickback arrangement is false per se once the underlying payment structure is established. Auditors and investigators trace this theory by following the money: distributor rebates, consulting fees paid to ordering clinicians, and marketer compensation calculated as a percentage of the reimbursement generated. A compensation arrangement tied to graft volume or graft size, rather than to a fixed, fair-market-value service, is the pattern that draws this theory.
Medical Necessity as an Independent Theory
The government's second theory does not require proof of a kickback at all. DOJ alleged that grafts were applied to wounds that did not need them, that graft sizes billed exceeded the wounds treated, and that grafts were applied on repeat visits after a wound had already healed. Each of these allegations stands on its own as a false claim, because Medicare pays only for care that is reasonable and necessary for the condition treated. The HHS Office of Inspector General's September 2025 data snapshot, which found Medicare Part B spending on skin substitutes had exceeded $10 billion in 2024, flagged first-visit graft applications without evidence of prior conservative wound care as a specific fraud indicator now driving referrals for investigation.
A claim can be false because the graft was never medically necessary, entirely apart from how the provider was paid to order it.
Marketer Conduct as a Basis for Liability
The third theory reaches conduct the treating provider may not have directed at all. In Apex Medical, sales representatives with no medical training identified Medicare beneficiaries in hospice and long-term care settings and directed which graft size to order for every patient, regardless of the wound presented. DOJ's position is that a physician or nurse practitioner who signs an order shaped by a marketer's product recommendation, without an independent clinical judgment behind it, exposes the practice to the same liability as the marketer. A practice's own billing pattern, tested against the product selection and frequency findings an auditor looks for, is the fastest way to see whether a marketing arrangement has already created this exposure.
Why Early Legal Counsel Is Critical
It is critical that wound care providers promptly retain experienced healthcare defense counsel upon receiving a subpoena, a civil investigative demand, an audit notice, or any other government inquiry touching skin substitute billing. Early legal intervention can protect the provider's rights, ensure appropriate responses to government requests, avoid inadvertent admissions, preserve every available defense, and let counsel communicate with investigators on the provider's behalf. Delaying representation can significantly affect the outcome of a matter and expose the provider to risk well beyond the underlying billing dispute.
How Health Law Alliance Can Help
Health Law Alliance defends wound care providers and physician practices against skin substitute False Claims Act investigations as part of the firm's broader wound care audit defense practice. Our team tests kickback exposure, medical necessity documentation, and marketer arrangements against the same three theories the government is using, before a recoupment demand becomes a referral. If your practice has received a subpoena, civil investigative demand, or audit notice tied to skin substitute billing, contact us for a free, confidential consultation.
